News stories about Myovant Sciences (NASDAQ:MYOV) have trended positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Myovant Sciences earned a coverage optimism score of 0.30 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.889777613808 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Myovant Sciences (NASDAQ MYOV) opened at 15.13 on Thursday. The firm’s market capitalization is $920.57 million. Myovant Sciences has a 12 month low of $9.92 and a 12 month high of $18.85. The company’s 50-day moving average price is $13.87 and its 200 day moving average price is $13.87.
Several research analysts recently commented on MYOV shares. Evercore ISI started coverage on Myovant Sciences in a research report on Wednesday, August 16th. They set an “outperform” rating for the company. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 16th. JMP Securities reissued an “outperform” rating and set a $25.00 price target (up from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Cowen and Company reissued a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. Finally, Robert W. Baird reissued a “buy” rating and set a $20.00 price target on shares of Myovant Sciences in a research report on Wednesday, October 4th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Myovant Sciences has an average rating of “Buy” and a consensus price target of $20.00.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/10/12/positive-news-coverage-somewhat-unlikely-to-affect-myovant-sciences-myov-share-price.html.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.